Does Testosterone Cause
Prostate Cancer?
For decades, men have been told that testosterone therapy increases prostate cancer risk. This belief is based on a misinterpretation of 80-year-old research. Here's what the current evidence — including the landmark TRAVERSE trial — actually shows.
Testosterone & Prostate Cancer: Myths vs. Evidence
Separating decades of fear from what peer-reviewed research actually demonstrates about testosterone and prostate cancer risk.
Testosterone causes prostate cancer
No large-scale, well-designed study has demonstrated a causal link between testosterone replacement therapy and prostate cancer. The Endocrine Society, AUA, and EAU guidelines all confirm that TRT does not increase prostate cancer risk in men without active disease.
Higher testosterone levels mean higher prostate cancer risk
The 'saturation model' (Morgentaler, 2006) demonstrates that prostate tissue becomes saturated at relatively low testosterone levels (~250 ng/dL). Above this threshold, additional testosterone does not further stimulate prostate growth.
Men who had prostate cancer can never use TRT
Emerging evidence supports cautious use of TRT in select men after successful prostate cancer treatment. Multiple studies show no increased recurrence in men on TRT post-radical prostatectomy, though this requires close clinical supervision.
TRT raises PSA dangerously
TRT may cause a modest initial PSA rise (typically 0.3–0.5 ng/mL), which stabilizes within 6–12 months. This is monitored routinely and does not indicate cancer development. Persistent or rapid PSA elevation warrants investigation regardless of TRT status.
How the Science Evolved
The fear of testosterone causing prostate cancer originated from a misinterpretation in 1941. Here's how 80 years of research corrected the record.
The Huggins Misunderstanding (1941)
Dr. Charles Huggins won a Nobel Prize for showing that castration (removing testosterone) could shrink advanced prostate cancer. This was incorrectly extrapolated to mean that testosterone causes prostate cancer — a logical fallacy that persisted for decades.
The Saturation Model (2006)
Dr. Abraham Morgentaler demonstrated that prostate tissue has a finite number of androgen receptors. Once saturated at low-normal testosterone levels (~250 ng/dL), additional testosterone cannot further stimulate prostate growth — debunking the dose-response myth.
The TRAVERSE Trial (2023)
The largest randomized TRT trial (5,246 men, 33-month median follow-up) found no statistically significant increase in prostate cancer incidence in men receiving testosterone versus placebo.
Meta-Analyses & Systematic Reviews
Multiple meta-analyses (including Boyle et al., 2016 and Corona et al., 2017) reviewing thousands of patients on TRT consistently show no increased risk of prostate cancer compared to untreated controls.
The Low Testosterone Paradox
Counterintuitively, research suggests that low testosterone is associated with more aggressive, higher-grade prostate cancers. Multiple studies have found that men diagnosed with prostate cancer who have low serum testosterone tend to have higher Gleason scores and worse outcomes.
A 2016 meta-analysis published in Medicine found that men with lower pre-treatment testosterone levels had significantly higher rates of aggressive prostate cancer compared to those with normal levels.
This doesn't mean low testosterone causes prostate cancer — but it challenges the outdated assumption that higher testosterone is the driver. The relationship is far more nuanced than "more testosterone = more cancer."
How We Monitor Prostate Safety During TRT
While the evidence is reassuring, responsible TRT always includes prostate monitoring. Here's our protocol.
Baseline PSA & Prostate Assessment
Every patient receives a baseline PSA test, digital rectal exam referral when indicated, and complete hormonal panel before initiating therapy.
Ongoing PSA Monitoring
PSA is tested at 3 months, 6 months, 12 months, and annually thereafter. Any rise exceeding 1.4 ng/mL from baseline or a PSA velocity >0.75 ng/mL/year triggers further investigation.
Expert Risk Stratification
Our clinical team evaluates family history, ethnicity, age, and baseline PSA to stratify prostate cancer risk before and during treatment — ensuring every patient receives individualized monitoring.
Evidence-Based Decision Framework
All protocols align with the Endocrine Society, AUA, and EAU clinical guidelines. We use shared decision-making so patients understand the evidence and feel confident in their treatment plan.
Key Takeaways
What every man considering testosterone therapy should know about prostate cancer risk.
Edmonton — Windermere
Windermere Plaza
213, 5540 Windermere Blvd, Edmonton, AB T6W 2Z8
Calgary — Silk Touch
Silk Touch
1102, 8561 8A Ave SW, Calgary, AB T3H 0V5